Compare AEHL & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEHL | BNGO |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 12.9M |
| IPO Year | 2009 | 2018 |
| Metric | AEHL | BNGO |
|---|---|---|
| Price | $0.69 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 155.2K | 130.5K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | N/A | $14.99 |
| Revenue Next Year | N/A | $34.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.34 | $1.06 |
| 52 Week High | $6.53 | $5.50 |
| Indicator | AEHL | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 43.93 |
| Support Level | $0.48 | $1.13 |
| Resistance Level | $1.13 | $1.19 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 30.76 | 11.11 |
Antelope Enterprise Holdings Ltd operates in three reportable operating segments: Business Management Consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting; Natural Gas Power generation, which was in the initial development stage; and Live-Streaming e-commerce segment, providing a one-stop solution for customers to enable them to utilize the growing sales channel of livestreaming ecommerce. The business of the Company is engaged in the PRC and the United States.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.